Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novo Nordisk wins EU...

    Novo Nordisk wins EU panel's backing for key diabetes drug

    Written by Ruby Khatun Khatun Published On 2017-12-18T10:30:27+05:30  |  Updated On 16 Aug 2021 2:59 PM IST

    COPENHAGEN: Danish drugmaker Novo Nordisk came closer to winning European approval for diabetes drug Ozempic, it's biggest growth prospect when a European Medicines Agency (EMA) experts' panel issued a positive recommendation on Friday.


    The once-weekly injection, known generically as semaglutide, is an important driver for offsetting the margin squeeze Novo Nordisk is experiencing in its traditional insulin franchise due to price pressure.


    The recommendation from EMA's Committee for Medicinal Products for Human Use would need to be formally endorsed by the European Commission before the drug can be marketed in the European Union. Novo Nordisk said it expects to receive final marketing authorization in the first quarter of 2018.


    Ozempic was approved by the U.S. Food and Drug Administration this month.


    Novo Nordisk hopes Ozempic will take market share from Eli Lilly's Trulicity, which has been cutting into sales of Novo's once-daily Victoza.


    Ozempic, Trulicity, and Victoza are all so-called glucagon-like peptide-1 (GLP-1) analogs, which imitate an intestinal hormone that stimulates the production of insulin.


    Analysts on average expect annual sales of Ozempic to reach $3.17 billion by 2023, with sales of Trulicity, which was approved in the United States in late 2014, reaching $3.71 billion over the same period, according to Thomson Reuters data.


    Ozempic is set to become Novo's biggest drug, according to analysts, who predict it will account for around 20 percent of sales in 2025.




    (Reporting by Stine Jacobsen; Editing by Adrian Croft and Susan Fenton)



    approvalbackingdiabetes drugEli LillyEU panelEuropeanEuropean Medicines AgencyinsulinNovo Nordiskonce-weekly injectionOzempicpharma newsprice pressuresemaglutideTrulicityU.S. Food and Drug AdministrationVictoza
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok